Remsima SC (subcutaneous) is a formulation of the biologic medication infliximab, designed for subcutaneous administration. Infliximab is a monoclonal antibody that targets and inhibits tumor necrosis factor-alpha (TNF-alpha), a substance in the body that causes inflammation and is involved in autoimmune diseases. Remsima SC is used in the treatment of various chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. This subcutaneous version offers an alternative to the intravenous (IV) infusions of infliximab, potentially providing more convenience for patients through self-administration at home, after initial supervision and approval from a healthcare provider.